Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b lenvatinib plus pembrolizumab in hepatocellular carcinoma
jRCT2080223439Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib and pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Started Jan 2017; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223439.